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INTRODUCTION
Hypothyroidism has various cardiovascular manifestations
including impaired diastolic function, reduced contractility
and infrequently pericardial effusion and heart failure (1-3).
Electrocardiographic (ECG) changes in hypothyroidism were
bradycardia, RBBB, flat or inverted T wave, QRS prolonga-
tion, QT prolongation and infrequently ventricular arrhyth-
mia, torsades de pointes (1-3). The QT interval reflects tra-
ditional electrocardiographic parameter of the duration of
ventricular repolarization. The QT dispersion is the interlead
variability of QT interval on surface ECG that reflects region-
al variations in myocardial repolarization. Increased the QT
dispersion has been linked to the occurrence of malignant
ventricular arrhythmias and sudden cardiac death (4-6). How-
ever, it was reported that the deficiency of thyroid hormone
did not affect ECG findings of congenitally hypothyroid neo-
nates (7). Therefore, the effects of L-thyroxine treatment on
ECG parameters, such as QT dispersion, in patients with pri-
mary hypothyroidism were examined.
MATERIALS AND METHODS
This retrospective study involved 18 patients (3 men, 15
women, age: 48±18 yr) with primary hypothyroidism. The
patient taking the QT-prolonging drugs or who had histo-
ries of cardiac disease were excluded. All patient were checked
with serum free T4, thyroid-stimulating hormone (TSH) and
standard 12-lead ECGs before and after L-thyroxine treatment.
After a rest period, the electrocardiogram had been checked
with 12-lead by electrocardiography recorder (25 mm/sec,
Marquette, Fairfield, Connecticut, U.S.A.). All measurements
were obtained manually by 1 observer unaware of patient
identity, diagnosis, and therapy. The QT interval was mea-
sured as the distance between onset of the QRS complex and
the end of the T wave in all 12-lead. When the U wave inter-
rupted, the end of the T wave was estimated by extrapolation
of the descending T-wave lined down to the baseline. Leads
without visible T waves were excluded from the analysis. The
QTc was calculated from Bazzett’s formula (QTc=QT/√RR).
The QTd was defined as the difference between the maximum
QT and the minimum QT across all 12 leads.
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The Effects of L-thyroxine Treatment on QT Dispersion in Primary
Hypothyroidism
Hypothyroidism has various cardiovascular manifestation and exhibits electrocar-
diographic change. The QT dispersion on surface ECG reflects regional variations
in myocardial repolarization. The effect of L-thyroxine treatment on ECG parame-
ters, such as QT dispersion, in patients with primary hypothyroidism were investi-
gated. This study involved 18 patients (3 men, 15 women, ages: 48± ±18 yr) with
primary hypothyroidism. All patients were checked with a standard 12-lead ECG
before and after L-thyroxine treatment. Various ECG parameters were then mea-
sured twice. The mean L-thyroxine treatment duration was 22± ±2.7 months. The
mean thyroid-stimulating hormone levels of patients before and after therapy were
40.2± ±29.8 U/mL,  3.6± ±4.6 U/mL  (p<0.001) and free-T4 levels were 0.44± ±0.38
ng/dL, 1.51± ±0.39 ng/dL (p<0.001). After L-thyroxine treatment, QT interval (395
± ±42 vs. 380± ±24 msec, p<0.05), QTc interval (434± ±32 vs. 417± ±23 msec, p<
0.05), QT dispersion (45± ±23 vs. 30± ±13 msec, p=0.008), QTc dispersion (49± ±
23 vs. 32± ±14 msec, p=0.005) significantly decreased. There were no significant
changes in the PR and RR intervals, as well as the QRS duration. Our findings sug-
gest that the thyroid hormone affects ventricular inhomogenicity, and that L-thyrox-
ine replacement therapy may reduce malignant ventricular arrhythmia and sudden
cardiac death in primary hypothyroidism.
Key Words : Hypothyroidism; Thyroxine; Electrocardiography
Received : 9 January 2006
Accepted : 3 July 2006L-thyroxine Affects QT Dispersion in Hypothyroidism  115
The data were analyzed using a statistical package (SPSS
Window 10.0 ver). Whenever the data could be paired, these
were analyzed using paired t-tests. The correlation was exam-
ined by the calculation of Pearson’s coefficient. A pvalue <0.05
was considered statistically significant.
RESULTS
Clinical characteristics
Of the 18 patients, 3 were men and 15 were women. The
mean age was 48±18 yr at the study baseline. The mean
follow-up duration was 22 months. The thyroid function test,
before and after L-thyroixine treatment, is shown in Table 1.
Baseline ECG
The QT prolongation was detected in 6 patients (33%) at
the study baseline. After the L-thyroxine treatment, 5 patients
were normalized. The T-inversion appeared in 3 patients, and
after the L-thyroxine treatment, all patients were normalized
(Fig. 1). The QTc prolongation correlated positively with the
baseline TSH level (r=0.484, p=0.042).
Electrocardiographic parameter
It was found that after the L-thyroxine treatment, the QT
interval (p<0.05), QTc interval (p<0.05), QT dispersion (p=
0.008), and the QTc dispersion (p=0.005) significantly dec-
reased. There were no significant changes in the PR interval,
RR interval, nor the QRS duration (Table 2).
DISCUSSION
The thyroid hormone affects the function of several human
organs even the heart. It is well documented that hypothy-
roidism affects cardiac functions and have various cardiovas-
cular manifestations including impaired diastolic functions,
reduced contractility and infrequently pericardial effusion
and heart failure. Hypothyroidism classically has been asso-
ciated with bradycardia, but the degree of slowing heart rate
is often modest. Other electrocardiographic changes in hypo-
thyroidism were RBBB, flat or inverted T waves, QRS pro-
longation, QT prolongation and infrequently ventricular arr-
hythmia, torsades de pointes (1-3). The function of the atrial
pacemaker is normal and atrial ectopy is rare, but premature
ventricular beats and occasionally ventricular tachycardia can
occur (8). This is in contrasts to thyrotoxicosis, in which atri-
al tachyarrhythmias are common and ventricular arrhythmias
are rare. The syndrome of torsade de pointes with a long QT
interval and ventricular tachycardia can occur with hypothy-
roidism and be resolved with T4 treatment alone (3, 9). 
The duration of the action potential may be prolonged,
perhaps reflecting a decrease in voltage-gated potassium cha-
nnels. Nathaniel et al. reported that significant prolongation
of the QTc interval occurred in inadequately treated hypothy-
roidism and the degree of the QTc prolongation was direct-
ly related to the severity of hypothyroidism (2). Altun et al.
showed that QT prologation and increased QTd were directly
related to the TSH levels in hypothyroidism (10). The QTd
reflects regional variations in myocardial repolarization. In-
*p<0.01.
Before LT4 treatment After LT4 treatment
TSH ( U/mL) 40.2±9.8 3.6±0.6*
free T4 (ng/dL) 0.44±0.38 1.51±0.39*
Table 1. Thyroid function tests before and after the L-thyroxine
treatment
*p<0.01.
Before LT4 treatment  After LT4 treatment
HR (beats/min) 69±10 72±11
PR (msec) 163±22 158±17
QRS (msec) 94±16 93±14
RR (msec) 835±159 831±115
QT (msec) 395±42 380±24*
QTc (msec) 434±32 417±23*
QTd (msec) 45±23 30±13* 
QTcd (msec) 49±23 32±14* 
Table 2. Variable parameters of ECG before and after L-thyrox-
ine (LT4) treatment
Fig. 1. Serial Electrocardiograms. (A) An ECG before L-thyroxine treatment shows QT prolongation (QTc=485 msec) and T-inversion in left
precordial leads. (B) An ECG after L-thyroxine treatment shows normal QT interval (QTc=432 msec) and an upright T-wave. 
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creased QTd has been found to be associated with an increased
incidence of malignant ventricular arrhythmias and sudden
death (4-6). The QTd provides a potentially simple, inexpen-
sive, noninvasive method of measuring underlying dispersion
recovery of ventricular excitability, and should be defined in
a way that most accurately reflects this state (11). Clinical
observations showed that ventricular arrhythmias and sud-
den death are uncommon in hypothyroidism, despite the
marked lengthening of the QT interval (3, 12, 13). Howev-
er, increased QTd in hypothyroidism may facilitate ventric-
ular arrhythmias with hypokalemia, hypomagnesemia, long
QT syndrome or drugs. 
Abnormal changes of heart rate variability measurements
and its improvement after treatment in hypothyroidism were
reported (14). However, the deficiency of the thyroid hor-
mone did not affect ECG findings of congenitally hypothy-
roid neonate (7). It was necessary to clarify the effects of L-
thyroxine treatment on ECG parameters in primary hypothy-
roidism. In this study, our results showed that the QTc and
QT dispersions improved after the L-thyroxine treatment in
patients with primary hypothyroidism. This suggests that
the thyroid hormone affects ventricular inhomogenicity, and
subsequent L-thyroxine replacement therapy may reduce
malignant ventricular arrhythmia and sudden cardiac death
in primary hypothyroidism.
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